New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic and paratopic diversity, enabling more effective identification and prioritization of therapeutic antibodies.